Intramyocardial patterning for treating localized anomalies of the heart

a technology of myocardial patterning and localized anomalies, which is applied in the field of intramyocardial patterning for treating localized anomalies of the heart, can solve the problems of heart failure, shortness of breath and fatigue, and accumulation of peripheral and abdominal fluids

Inactive Publication Date: 2008-03-13
CARDIOPOLYMERS +2
View PDF53 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Left ventricular failure typically causes shortness of breath and fatigue, and right ventricular failure typically causes peripheral and abdominal fluid accumulation.
Cardiomyopathy typically results in heart failure.
Right ventricular failure may follow.
Moreover, transplantation is not the most suitable treatment option for patients with milder forms of the disease.
A myocardial infarction may progressively advance into heart failure.
It is believed that the death of cardiomyocytes results in negative left ventricular (LV) remodeling which leads to increased wall stress in the remaining viable myocardium.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Intramyocardial patterning for treating localized anomalies of the heart
  • Intramyocardial patterning for treating localized anomalies of the heart
  • Intramyocardial patterning for treating localized anomalies of the heart

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0052] As described herein, cardiomyopathy may be treated by distributing a space-occupying agent within the myocardium in a pattern about one or more chambers of the heart, such that the space-modifying agent integrates into and thickens at least part of the cardiac wall about the chamber so as globally to reduce wall stress and stabilize or even reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function. Over time the relief of wall stress reduces oxygen consumption and promotes healing. Moreover, various long-term therapeutic effects may be realized depending on the properties of the space-occupying agent, including combinations with other therapeutic materials. Specific cardiac conditions treatable by these systems and methods include, for example, dilated cardiomyopathy (with or without overt aneurismal formations), congestive...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
areaaaaaaaaaaa
biocompatibleaaaaaaaaaa
Login to view more

Abstract

Cardiomyopathy may be treated by distributing space-occupying agent within the myocardium in a pattern about one or more chambers of the heart, such that the space-modifying agent integrates into and thickens at least part of the cardiac wall about the chamber so as globally to reduce wall stress and stabilize or even reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function. Over time the relief of wall stress reduces oxygen consumption and promotes healing. Moreover, various long-term therapeutic effects may be realized depending on the properties of the space-occupying agent, including combinations with other therapeutic materials. Specific cardiac conditions treatable by these systems and methods include, for example, dilated cardiomyopathy (with or without overt aneurismal formations), congestive heart failure, and ventricular arrhythmias. Patterns of distribution of space-occupying agent within the myocardium for global resizing may also be used or augmented to treat localized conditions such as myocardial infarctions, overt aneurysm of the ventricular wall as typically forms in response to large transmural myocardial infarctions, and mitral regurgitation due to a noncompliant mitral valve. These techniques may also be used to treat localized conditions that may not yet have progressed to cardiomyopathy.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Patent Application Ser. No. 60 / 843,475 filed Sep. 8, 2006, which hereby is incorporated herein in its entirety by reference thereto. This application is a continuation-in-part of U.S. patent application Ser. No. 11 / 129,046 filed May 12, 2005, which is a continuation of International Patent Application Serial No. PCT / US03 / 23162 filed Jul. 25, 2003, which clams the benefit of U.S. Provisional Patent Application Ser. No. 60 / 429,914 filed Nov. 29, 2002, and of U.S. Provisional Patent Application Ser. No. 60 / 431,287 filed Dec. 6, 2002, all of which hereby are incorporated herein in their entirety by reference thereto.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates to treatment of cardiac conditions in living beings, and more particularly to the use of intramyocardial patterning for treating localized anomalies of the heart. [0004] 2. Des...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61M31/00
CPCA61F2/2451A61F2/2481A61L27/3873A61F2250/0067A61F2002/249A61P9/00A61K9/0024A61L27/20A61L27/52A61L2400/06A61M5/14A61M5/178A61M37/00A61M37/0069
Inventor SABBAH, HANI N.LEE, RANDALL J.HINSON, ANDREW G.
Owner CARDIOPOLYMERS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products